PeptideHelper.org
Your evidence-based peptide reference
Research reference only. Not medical advice. Most compounds are not FDA-approved. Consult a qualified clinician before any human use.

Weight Loss & Metabolic

Liraglutide

NN2211; Saxenda; Victoza

Classification: GLP-1 receptor agonist

Mechanism: GLP-1R agonist; albumin-binding fatty acid extends half-life

Benefits: T2D glycemic control; weight loss ~5-10% (Saxenda); cardiovascular protection

Evidence tier: FDA-Approved · Availability: Prescription

Primary sources

  1. FDA Saxenda (liraglutide) prescribing information for chronic weight management
  2. FDA Victoza (liraglutide) prescribing information
  3. Pi-Sunyer X et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE Obesity and Prediabetes). N Engl J Med 2015. PMID 26132939
  4. Marso SP et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med 2016. PMID 27295427

Loading interactive view…